Potent inhibition of HIV-1 replication by novel non-peptidyl small molecule inhibitors of protease dimerization

被引:103
作者
Koh, Yasuhiro
Matsumi, Shintaro
Das, Debananda
Amano, Masayuki
Davis, David A.
Li, Jianfeng
Leschenko, Sofiya
Baldridge, Abigail
Shioda, Tatsuo
Yarchoan, Robert
Ghosh, Arun K.
Mitsuya, Hiroaki
机构
[1] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Hematol, Kumamoto 8608556, Japan
[2] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Dept Infect Dis, Kumamoto 8608556, Japan
[3] NCI, NIH, Expt Retrovirol Sect, Bethesda, MD 20892 USA
[4] NCI, NIH, Retroviral Dis Sect, HIV & AIDS Malignancy Branch, Bethesda, MD 20892 USA
[5] Purdue Univ, Dept Chem & Med Chem, W Lafayette, IN 47907 USA
[6] Osaka Univ, Dept Viral Infect, Res Inst Microbial Dis, Osaka 5650871, Japan
关键词
D O I
10.1074/jbc.M703938200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Dimerization of HIV-1 protease subunits is essential for its proteolytic activity, which plays a critical role in HIV-1 replication. Hence, the inhibition of protease dimerization represents a unique target for potential intervention of HIV-1. We developed an intermolecular fluorescence resonance energy transfer-based HIV-1-expression assay employing cyan and yellow fluorescent protein-tagged protease monomers. Using this assay, we identified non-peptidyl small molecule inhibitors of protease dimerization. These inhibitors, including darunavir and two experimental protease inhibitors, blocked protease dimerization at concentrations of as low as 0.01 mu M and blocked HIV-1 replication with IC50 values of 0.0002-0.48 mu M. These agents also inhibited the proteolytic activity of mature protease. Other approved anti-HIV-1 agents examined except tipranavir, a CCR5 inhibitor, and soluble CD4 failed to block the dimerization event. Once protease monomers dimerize to become mature protease, mature protease is not dissociated by this dimerization inhibition mechanism, suggesting that these agents block dimerization at the nascent stage of protease maturation. The proteolytic activity of mature protease that managed to undergo dimerization despite the presence of these agents is likely to be inhibited by the same agents acting as conventional protease inhibitors. Such a dual inhibition mechanism should lead to highly potent inhibition of HIV-1.
引用
收藏
页码:28709 / 28720
页数:12
相关论文
共 48 条
  • [1] A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro
    Amano, Masayuki
    Koh, Yasuhiro
    Das, Debananda
    Li, Jianfeng
    Leschenko, Sofiya
    Wang, Yuan-Fang
    Boross, Peter I.
    Weber, Irene T.
    Ghosh, Arun K.
    Mitsuya, Hiroaki
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (06) : 2143 - 2155
  • [2] SYNTHETIC INTERFACE PEPTIDES ALTER DIMERIC ASSEMBLY OF THE HIV-1 AND HIV-2 PROTEASES
    BABE, LM
    ROSE, J
    CRAIK, CS
    [J]. PROTEIN SCIENCE, 1992, 1 (10) : 1244 - 1253
  • [3] Molecular tongs containing amino acid mimetic fragments:: New inhibitors of wild-type and mutated HIV-1 protease dimerization
    Bannwarth, Ludovic
    Kessler, Albane
    Pethe, Stephanie
    Collinet, Bruno
    Merabet, Naima
    Boggetto, Nicole
    Sicsic, Sames
    Reboud-Ravaux, Michele
    Ongeri, Sandrine
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (15) : 4657 - 4664
  • [4] Imaging the intracellular trafficking and state of the AB(5) quaternary structure of cholera toxin
    Bastiaens, PIH
    Majoul, IV
    Verveer, PJ
    Soling, HD
    Jovin, TM
    [J]. EMBO JOURNAL, 1996, 15 (16) : 4246 - 4253
  • [5] Microspectroscopic imaging tracks the intracellular processing of a signal transduction protein: Fluorescent-labeled protein kinase C beta I
    Bastiaens, PIH
    Jovin, TM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) : 8407 - 8412
  • [6] Switching between allosteric and dimerization inhibition of HIV-1 protease
    Bowman, MJ
    Byrne, S
    Chmielewski, J
    [J]. CHEMISTRY & BIOLOGY, 2005, 12 (04): : 439 - 444
  • [7] Toxicity of antiretroviral therapy and implications for drug development
    Carr, A
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (08) : 624 - 634
  • [8] Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease
    Davis, David A.
    Brown, Cara A.
    Singer, Kathleen E.
    Wang, Victoria
    Kaufman, Joshua
    Stahl, Stephen J.
    Wingfield, Paul
    Maeda, Kenji
    Harada, Shigeyoshi
    Yoshimura, Kazuhisa
    Kosalaraksa, Pope
    Mitsuya, Hiroaki
    Yarchoan, Robert
    [J]. ANTIVIRAL RESEARCH, 2006, 72 (02) : 89 - 99
  • [9] TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates
    De Meyer, S
    Azijn, H
    Surleraux, D
    Jochmans, D
    Tahri, A
    Pauwels, R
    Wigerinck, P
    de Béthune, MP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (06) : 2314 - 2321
  • [10] PCR-mediated recombination: A general method applied to construct chimeric infectious molecular clones of plasma-derived HIV-1 RNA
    Fang, GW
    Weiser, B
    Visosky, A
    Moran, T
    Burger, H
    [J]. NATURE MEDICINE, 1999, 5 (02) : 239 - 242